Kairos Pharma Ltd. (NYSE American: KAPA) has been named the recipient of the 2026 Biotech Breakthrough Award for Cancer Immunology Solution of the Year for its investigational therapy ENV-105 (carotuximab). The award recognizes the clinical-stage company's efforts to address a major challenge in oncology: treatment resistance that limits the long-term effectiveness of existing cancer therapies.
ENV-105 is a neutralizing antibody designed to target CD105, a protein that Kairos identifies as a key driver of resistance and disease relapse following standard treatment. By blocking CD105, the therapy aims to reverse drug resistance and restore the effectiveness of conventional therapies across multiple cancer types. The company is currently evaluating ENV-105 in combination with standard-of-care treatments in metastatic prostate cancer and non-small cell lung cancer.
The recognition comes on the heels of positive interim efficacy data from an ongoing Phase 2 trial of ENV-105 in combination with apalutamide in patients with metastatic castration-resistant prostate cancer. According to the company, the interim analysis demonstrated a statistically significant difference in progression-free survival between patients receiving the combination therapy and those receiving apalutamide alone. That data point is significant because it provides early clinical validation for the CD105-targeting mechanism and could bolster the therapy's path toward further development.
For investors and industry observers, the award and the interim data together signal that Kairos Pharma may be onto a differentiated approach in a crowded immuno-oncology landscape. The ability to extend the benefit of existing treatments rather than developing an entirely new monotherapy could offer a faster, more cost-effective route to addressing unmet needs in prostate and lung cancers. The full press release can be viewed at https://ibn.fm/GnUxn.
Kairos Pharma, based in Los Angeles, California, is focused on using structural biology to overcome drug resistance and immune suppression in cancer. ENV-105 is its lead candidate, and the company believes it could be applied across multiple cancer types where CD105 plays a role in resistance and relapse. The award adds external validation to that thesis, potentially raising the company's profile among potential partners and investors.
Latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA. The announcement was distributed through BioMedWire, a specialized communications platform focused on the biotechnology, biomedical sciences, and life sciences sectors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions through InvestorWire and other services. The platform offers editorial syndication to 5,000+ outlets and social media distribution, among other corporate communications solutions.


